PLX PROTALIX BIOTHERAPEUTICS INC Capital Structure Changes 8-K Filing 2025 - Stock Offering On March 17, 2025, Protalix Biotherapeutics amended its agreement to increase the amount of common stock it can sell by $20 million for general corporate purposes, including funding clinical trials.Get access to all SEC 8-K filings of the PROTALIX BIOTHERAPEUTICS INC